Next-generation Sequencing

A Powerful Tool for the Discovery of Molecular Markers in Breast Ductal Carcinoma In Situ

Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly


Expert Rev Mol Diagn. 2013;13(2):151-165. 

In This Article

Five-year View

Many challenges still remain, such as establishing effective analytical tools for the enormous amounts of data generated by the sequencing technologies. Future directions should also explore the intratumoral heterogeneity of DCIS by sequencing of single cells and by subpopulation analysis. A complete picture will require the analysis of stromal components and infiltrating cells as well. The integrated approaches that will take into account the complete classification of diverse DCIS lesions are still being developed. Further advances in NGS and bioinformatics approaches, along with reduced costs and increased availability, should move us closer to personalized therapy for DCIS. Integration of the sequencing data from multiple collaborative teams with the available clinical data using computational tools and network modeling approaches may elucidate underlying driver mechanisms and result in the identification of robust biomarkers that can stratify DCIS patients and eventually improve treatment decisions.